Skip to main content

Advertisement

SpringerLink
Log in

The epigenetics pipeline

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Epigenetic drugs by phase of clinical development and mechanism of action.

References

  1. Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148–1159 (2008).

    Article  CAS  Google Scholar 

  2. Arrowsmith, C. H. et al. Epigenetic protein families: a new frontier for drug discovery. Nature Rev. Drug Discov. 11, 384–400 (2012).

    Article  CAS  Google Scholar 

  3. Burridge, S. Drugging the epigenome. Nature Rev. Drug Discov. 12, 92–93 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Trinity Partners, 675 Third Avenue, 20th Floor, New York, 10017, New York, USA

    Vivian A. DeWoskin & Ryan P. Million

Authors
  1. Vivian A. DeWoskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryan P. Million
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Vivian A. DeWoskin or Ryan P. Million.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

DeWoskin, V., Million, R. The epigenetics pipeline. Nat Rev Drug Discov 12, 661–662 (2013). https://doi.org/10.1038/nrd4091

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4091

  • Springer Nature Limited

This article is cited by

Search

Navigation